Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy
oleh: Justina Dargvainiene, Ulf Jensen‐Kondering, Benjamin Bender, Daniela Berg, Norbert Brüggemann, Charlotte Flüh, Robert Markewitz, Alexander Neumann, Benjamin Röben, Christoph Röcken, Georg Royl, Claudia Schulte, Klaus‐Peter Wandinger, Caroline Weiler, Nils G. Margraf, Gregor Kuhlenbäumer
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2024-03-01 |
Deskripsi
Abstract Differential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of Aβ38 and Aβ43 to a standard AD biomarker panel (Aβ40, Aβ42, t‐tau, p‐tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding Aβ38 and Aβ43 to the panel did not improve the discrimination between AD and CAA.